Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR- mutated non-small-cell lung cancer

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including . mutation status is required to optimally treat patients with nsclc,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Current oncology (Toronto) 2020-12, Vol.27 (6), p.321-329
Hauptverfasser:	Cheema, P K, Gomes, M, Banerji, S, Joubert, P, Leighl, N B, Melosky, B, Sheffield, B S, Stockley, T, Ionescu, D N
Format:	Artikel
Sprache:	eng
Schlagworte:	Practice Guideline
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!